Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Catalyst Grant: Analysis of CLSA Data - IA Early Career Researchers

McGill University

$70,000.00

Understanding causal effects of circulating proteins and metabolites on human diseases for drug target discovery: A genetic epidemiology study with CLSA

FY 2024-25

Summary
Proteins and metabolites are key players in the development of many diseases, such as diabetes, coronary artery disease, osteoporosis, and other conditions affecting aging populations. Molecules that cause diseases can serve as important drug targets. However, because they are involved in complex biological systems, it is challenging to identify which molecules cause diseases, rather than being consequences or mere bystanders, known as confounding. Mendelian randomization (MR) is a genetic epidemiology method that can evaluate the causal effects of various factors on diseases using genetic variations. By leveraging large-scale genetic data from genome-wide association studies (GWAS) of proteins, metabolites, and diseases, MR can rapidly and systematically identify causal proteins or metabolites. Our project will use MR to evaluate the causal effects of 2,265 proteins and 1,091 metabolites on more than 500 diseases and risk factors measured in the Canadian Longitudinal Study on Aging (CLSA). Since MR requires GWAS data, we will first generate GWAS for these diseases and risk factors using our established pipeline with CLSA data. We will also perform sex-stratified GWAS analyses to assess potential differences between men and women. Next, we will use these GWAS along with publicly available GWAS of protein and metabolite levels to estimate the causal effects of these molecules on diseases through MR. We will also perform sex-stratified MR to assess how these associations may differ by sex. Finally, we will assess whether these molecules are targeted by existing drugs or compounds using multiple drug databases, such as Open Targets and DrugBank. In summary, this study will use genomics, proteomics, and metabolomics data from the CLSA with advanced genetic methods to systematically identify proteins and metabolites that influence risk of human diseases. By doing so, we aim to understand the molecular mechanisms driving these diseases and identify new drug targets.
Program
Catalyst Grant: Analysis of CLSA Data - IA Early Career Researchers
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
521882
Name
Yoshiji Satoshi
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Genetics
Theme2
Health systems / services
Prcname2
Catalyst Grant: Analysis of CLSA Data
Projecttitle
Understanding causal effects of circulating proteins and metabolites on human diseases for drug target discovery: A genetic epidemiology study with CLSA
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$70,000
Cihrequipment2
$0
Programname2
Catalyst Grant: Analysis of CLSA Data - IA Early Career Researchers
Keyworddelim
Aging; Causal Inference; Drug Target Discovery; Genome-Wide Association Studies; Genomics; Mendelian Randomization; Metabolomics; Omics; Proteomics
Abstract
Proteins and metabolites are key players in the development of many diseases, such as diabetes, coronary artery disease, osteoporosis, and other conditions affecting aging populations. Molecules that cause diseases can serve as important drug targets. However, because they are involved in complex biological systems, it is challenging to identify which molecules cause diseases, rather than being consequences or mere bystanders, known as confounding. Mendelian randomization (MR) is a genetic epidemiology method that can evaluate the causal effects of various factors on diseases using genetic variations. By leveraging large-scale genetic data from genome-wide association studies (GWAS) of proteins, metabolites, and diseases, MR can rapidly and systematically identify causal proteins or metabolites. Our project will use MR to evaluate the causal effects of 2,265 proteins and 1,091 metabolites on more than 500 diseases and risk factors measured in the Canadian Longitudinal Study on Aging (CLSA). Since MR requires GWAS data, we will first generate GWAS for these diseases and risk factors using our established pipeline with CLSA data. We will also perform sex-stratified GWAS analyses to assess potential differences between men and women. Next, we will use these GWAS along with publicly available GWAS of protein and metabolite levels to estimate the causal effects of these molecules on diseases through MR. We will also perform sex-stratified MR to assess how these associations may differ by sex. Finally, we will assess whether these molecules are targeted by existing drugs or compounds using multiple drug databases, such as Open Targets and DrugBank. In summary, this study will use genomics, proteomics, and metabolomics data from the CLSA with advanced genetic methods to systematically identify proteins and metabolites that influence risk of human diseases. By doing so, we aim to understand the molecular mechanisms driving these diseases and identify new drug targets.
Competitiondate
202410
Approvedterm2
1 yr 0 mth
Pinamesdelim
Yoshiji, Satoshi
Approvedterm
1 an 0 mois
Cihrcontribution2
IA~ $70,000~ $0~